MarketCapExport financials
Infinity Pharmaceuticals (INFI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Infinity Pharmaceuticals Balance Sheet 2022-2008 | INFI
Brief overview of Infinity Pharmaceuticals's balance sheet strength
The review uses the five latest available annual reports between 2018 and 2022.
Assets declined from $60.2 million to $42.2 million, or -30%. The contraction calls for context such as disposals, restructuring or weaker operations.
Liabilities expanded faster than the asset base, +689.1% versus -30%. Debt-service capacity deserves attention.
The period ended with negative equity, a structure associated with elevated financial vulnerability.
The balance sheet holds more cash than interest-bearing debt; net debt is -$37.4 million, indicating minimal leverage.
The cash share moved from 80.7% to 90.9%. A higher figure generally provides more room in an adverse scenario.
Retained earnings remain negative at -$856 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Balance sheet takeaway
Infinity Pharmaceuticals's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Infinity Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-37.4 M | -79.3 M | -26.7 M | -20 M | -48.6 M | -28.6 M | -54.5 M | -168 M | -292 M | -61.7 M | -176 M | 13.4 M | - | - | - |
Long Term Debt |
324 K | 917 K | 1.44 M | 1.93 M | - | - | - | - | - | 6.46 M | - | 37.6 M | - | - | - |
Long Term Debt Current |
593 K | 519 K | 489 K | 381 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 51.3 M | 31.6 M | 38 K | 28 K | 19.3 M | 120 M | 105 M | 7.23 M | 6.79 M | 80.1 M | - | - | - |
Total Current Liabilities |
13.6 M | 13.3 M | 11 M | 9.7 M | 7.72 M | 11.6 M | 23.9 M | 70.1 M | 54.9 M | 22.2 M | 18.7 M | 29 M | 27.8 M | - | - |
Total Liabilities |
61.2 M | 63.2 M | 62.3 M | 41.3 M | 7.76 M | 11.6 M | 43.2 M | 190 M | 160 M | 29.4 M | 25.5 M | 109 M | 75.1 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 35.4 M | 24.5 M | - | - | 4.22 M | 4.78 M | - | - |
Retained Earnings |
-856 M | -812 M | -766 M | -726 M | -679 M | -668 M | -626 M | -596 M | -467 M | -450 M | -323 M | -269 M | -229 M | - | - |
Total Assets |
42.2 M | 84.8 M | 39.3 M | 49 M | 60.2 M | 59.4 M | 126 M | 289 M | 369 M | 231 M | 336 M | 124 M | 125 M | - | - |
Cash and Cash Equivalents |
38.3 M | 80.7 M | 28.6 M | 22.3 M | 48.6 M | 34.6 M | 74.1 M | 188 M | 307 M | 68.1 M | 176 M | 24.2 M | 20.4 M | 16.3 M | 16.6 M |
Book Value |
-19.1 M | 21.6 M | -23 M | 7.73 M | 52.5 M | 47.7 M | 82.5 M | 98.6 M | 209 M | 201 M | 310 M | 15.4 M | 49.5 M | - | - |
Total Shareholders Equity |
-19.1 M | 21.6 M | -23 M | 7.73 M | 52.5 M | 47.7 M | 82.5 M | 98.6 M | 209 M | 201 M | 310 M | 15.4 M | 49.5 M | 90.3 M | 103 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Infinity Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 164 K | 324 K | 480 K | 633 K | 777 K | 917 K | 1.05 M | 1.19 M | 1.31 M | 1.44 M | 1.56 M | 1.69 M | 1.81 M | 1.93 M | 1.96 M | 1.85 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
58.6 M | 58.3 M | 61.2 M | 62.5 M | 63 M | 62.6 M | 63.2 M | 62.5 M | 61.1 M | 60.4 M | 62.3 M | 61.1 M | 60 M | 59.3 M | 41.3 M | 40.5 M | 38.9 M | 35.3 M | 7.76 M | 6.14 M | 5.71 M | 4.57 M | 11.6 M | 10.9 M | 31.9 M | 29.8 M | 43.2 M | 49.8 M | 68.5 M | 179 M | 190 M | 200 M | 154 M | 147 M | 160 M | 151 M | 27.1 M | 26.7 M | 29.4 M | 30.6 M | 27.8 M | 24.1 M | 25.5 M | 18.5 M | 116 M | 108 M | 109 M | 69.6 M | 66.4 M | 109 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.3 M | 35.4 M | 39.8 M | 30.6 M | 26.1 M | 24.5 M | 22 M | 24.5 M | 24.5 M | - | - | - | - | - | 4.22 M | 14 M | 7.58 M | 4.22 M | 4.21 M | 4.57 M | 4.22 M |
Retained Earnings |
-877 M | -867 M | -856 M | -847 M | -836 M | -824 M | -812 M | -800 M | -789 M | -778 M | -766 M | -756 M | -746 M | -737 M | -726 M | -714 M | -703 M | -693 M | -679 M | -671 M | -684 M | -677 M | -668 M | -660 M | -653 M | -636 M | -626 M | -603 M | -583 M | -636 M | -596 M | -556 M | -599 M | -561 M | -467 M | -427 M | -530 M | -492 M | -450 M | -417 M | -383 M | -350 M | -323 M | -276 M | -294 M | -280 M | -269 M | -255 M | -243 M | -269 M |
Total Assets |
21.2 M | 30 M | 42.2 M | 51.6 M | 61.9 M | 72.6 M | 84.8 M | 94.6 M | 103 M | 112 M | 39.3 M | 47 M | 48.7 M | 57.1 M | 49 M | 59.1 M | 68.4 M | 74.7 M | 60.2 M | 65.9 M | 51.3 M | 50 M | 59.4 M | 64.3 M | 90.8 M | 104 M | 126 M | 152 M | 187 M | 240 M | 289 M | 333 M | 241 M | 268 M | 369 M | 397 M | 166 M | 200 M | 231 M | 261 M | 288 M | 313 M | 336 M | 198 M | 113 M | 115 M | 124 M | 97.7 M | 105 M | 124 M |
Cash and Cash Equivalents |
17.7 M | 25.7 M | 38.3 M | 47.2 M | 45.8 M | 53.1 M | 80.7 M | 90.1 M | 97.3 M | 107 M | 28.9 M | 18.5 M | 28.9 M | 30.5 M | 22.3 M | 21.6 M | 42.6 M | 52.9 M | 48.6 M | 32.2 M | 49.2 M | 30.6 M | 34.6 M | 33.6 M | 66.2 M | 75.4 M | 74.1 M | 98.5 M | 122 M | 114 M | 188 M | 137 M | 135 M | 223 M | 307 M | 321 M | 85.5 M | 55 M | 68.1 M | 53.5 M | 55.2 M | 101 M | 176 M | 52.9 M | 19.7 M | 23.5 M | 24.2 M | 23.1 M | 17.5 M | 24.2 M |
Book Value |
-37.4 M | -28.3 M | -19.1 M | -10.9 M | -1.11 M | 9.98 M | 21.6 M | 32.1 M | 41.5 M | 52 M | -23 M | -14.1 M | -11.4 M | -2.25 M | 7.73 M | 18.6 M | 29.6 M | 39.4 M | 52.5 M | 59.8 M | 45.6 M | 45.4 M | 47.7 M | 53.4 M | 58.9 M | 73.8 M | 82.5 M | 102 M | 119 M | 61.6 M | 98.6 M | 134 M | 87.3 M | 121 M | 209 M | 246 M | 138 M | 173 M | 201 M | 230 M | 260 M | 289 M | 310 M | 180 M | -3.39 M | 6.96 M | 15.4 M | 28.1 M | 38.4 M | 15.4 M |
Total Shareholders Equity |
-37.4 M | -28.3 M | -19.1 M | -10.9 M | -1.11 M | 9.98 M | 21.6 M | 32.1 M | 41.5 M | 52 M | -23 M | -14.1 M | -11.4 M | -2.25 M | 7.73 M | 18.6 M | 29.6 M | 39.4 M | 52.5 M | 59.8 M | 45.6 M | 45.4 M | 47.7 M | 53.4 M | 58.9 M | 73.8 M | 82.5 M | 102 M | 119 M | 61.6 M | 98.6 M | 134 M | 87.3 M | 121 M | 209 M | 246 M | 138 M | 173 M | 201 M | 230 M | 260 M | 289 M | 310 M | 180 M | -3.39 M | 6.96 M | 15.4 M | 28.1 M | 38.4 M | 15.4 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Infinity Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Russia
France
Israel
Britain
Irlanda
China
Japan
Singapore
